All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) experience high response rates with CD19-directed chimeric antigen receptor (CAR) T cells; however, there is a risk of relapse and often considerable toxicity.
Here, we summarize the outcomes of the phase II TARMAC (NCT04234061) trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and CTL019 CAR T-cells in patients with relapsed/refractory mantle cell lymphoma (MCL).
Figure 1. Response to treatment*
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
*Adapted from Minson, et al.1
†14 patients were MRD negative by flow cytometry.
Two patients developed reversible Grade 1–2 neurotoxicity.
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox